Category: Health
The FDA approved Guardant Health's blood test, Shield, for colon cancer screening, which could increase screening rates. While it is not a replacement for colonoscopies, it is expected to be more accessible with insurance coverage. The test is 83% effective in detecting colorectal cancers but primarily identifies later-stage cancers. A positive result still requires a follow-up colonoscopy for confirmation. The approval comes amid rising colon cancer rates in younger populations, highlighting the need for improved screening methods.
Keywords: colon cancer, FDA approval, blood test
Update At: 7/30/2024